
MorphoSys AG MOR
Annual report 2023
added 12-27-2025
MorphoSys AG Operating Expenses 2011-2026 | MOR
Annual Operating Expenses MorphoSys AG
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 432 M | 450 M | 656 M | 301 M | 168 M | 137 M | 134 M | 110 M | 93.4 M | 69.8 M | 68 M | 49.5 M | 81.6 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 656 M | 49.5 M | 211 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 16.93 | -2.14 % | $ 791 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 7.45 | -4.85 % | $ 204 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
AbCellera Biologics
ABCL
|
292 M | $ 4.09 | -7.16 % | $ 1.22 B | ||
|
Coherus BioSciences
CHRS
|
231 M | $ 1.57 | -3.68 % | $ 184 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.62 | 1.76 % | $ 431 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
BioNTech SE
BNTX
|
512 M | $ 89.73 | -2.46 % | $ 21.7 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.38 | -3.15 % | $ 5.56 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 0.73 | -0.15 % | $ 33.4 M | ||
|
Eton Pharmaceuticals
ETON
|
43.6 M | $ 29.89 | -0.23 % | $ 804 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
343 M | $ 3.13 | 0.16 % | $ 651 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Exelixis
EXEL
|
598 M | $ 50.21 | -1.74 % | $ 13.6 B | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.61 | 0.19 % | $ 2.75 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Fortress Biotech
FBIO
|
125 M | $ 2.42 | 5.0 % | $ 67.5 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Forte Biosciences
FBRX
|
70.7 M | $ 22.57 | -5.8 % | $ 292 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 9.66 | 4.6 % | $ 276 M | ||
|
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M |